Eqis Capital Management Inc. Has $2.26 Million Stake in Pfizer Inc. (PFE)

Eqis Capital Management Inc. lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 69.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 63,349 shares of the biopharmaceutical company’s stock after purchasing an additional 26,064 shares during the period. Eqis Capital Management Inc.’s holdings in Pfizer were worth $2,262,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Janus Henderson Group PLC increased its holdings in shares of Pfizer by 243.5% during the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after acquiring an additional 9,339,749 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares during the last quarter. Renaissance Technologies LLC acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $268,389,000. Canada Pension Plan Investment Board increased its holdings in shares of Pfizer by 249.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after acquiring an additional 7,649,416 shares during the last quarter. Finally, Parametric Portfolio Associates LLC increased its holdings in shares of Pfizer by 42.1% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 17,818,368 shares of the biopharmaceutical company’s stock worth $598,519,000 after acquiring an additional 5,281,314 shares during the last quarter. Institutional investors own 69.89% of the company’s stock.

A number of research firms recently weighed in on PFE. BMO Capital Markets set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a report on Friday. Deutsche Bank set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Barclays set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 price objective on Pfizer and gave the company a “neutral” rating in a report on Monday, October 16th. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $38.77.

In other news, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the sale, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.

Shares of Pfizer Inc. (PFE) opened at $37.20 on Monday. The stock has a market capitalization of $221,708.50, a price-to-earnings ratio of 14.88, a PEG ratio of 2.62 and a beta of 1.01. Pfizer Inc. has a 1-year low of $30.90 and a 1-year high of $37.22. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. Pfizer’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.61 EPS. research analysts anticipate that Pfizer Inc. will post 2.59 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Friday, December 1st. Stockholders of record on Friday, November 10th were issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 3.44%. The ex-dividend date of this dividend was Thursday, November 9th. Pfizer’s dividend payout ratio (DPR) is currently 79.01%.

ILLEGAL ACTIVITY WARNING: “Eqis Capital Management Inc. Has $2.26 Million Stake in Pfizer Inc. (PFE)” was originally published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://stocknewstimes.com/2017/12/18/eqis-capital-management-inc-has-2-26-million-stake-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply